Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon board meetings
141 filed, newest first. Page 3 of 3.
Jul 2016
Apr 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
Jan 2015
5 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended December 31, 2014.
Oct 2014
1 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2014.
Jul 2014
1 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2014.
Apr 2014
2 Apr · Board meeting
Inter alia, to: (a) Approve and take on record the audited financial results for the year ended on March 31, 2014. (b) Consider recommendation for payment of dividend, if any, for the year 2013-2014.
Jan 2014
2 Jan · Board meeting
Inter alia to approve and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013.
Oct 2013
4 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2013.
Jul 2013
26 Jul · Board meeting
Board of Directors of the Company have noted the proposal for merger of its subsidiary Clinigene International Limited with Syngene International Limited, at its meeting held on July 25, 2013.3 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2013.
Apr 2013
9 Apr · Board meeting
Inter alia, to: (a) Approve and take on record the audited Financial results for the year ended on March 31, 2013.and (b) Consider recommendation of payment of dividend, if any, for the year 2012-2013.
Jan 2013
8 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2012.
Oct 2012
15 Oct · Board meeting
Inter alia, to : (1) Approve and take on record the unaudited financial results of the Company for the quarter and half year ended on September 30, 2012.
Jul 2012
16 Jul · Board meeting
Inter alia to : (a) Approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2012; (b) Consider merger of Biocon Biopharmaceuticals Limited, a wholly owned subsidiary with the Company.
Apr 2012
17 Apr · Board meeting
Inter alia, to approve and take on record the audited financial results of the Company for the year ended on March 31, 2012 and to consider recommendation of payment of dividend, if any, for the year 2011-2012.
Jan 2012
5 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2011.
Oct 2011
17 Oct · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 20, 2011 inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2011. The Company has now informed the Exchange that the aforesaid Board Meeting has been preponed and will now be held on October 19, 2011.Not held on this date
11 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2011.
Jul 2011
1 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2011.
Apr 2011
18 Apr · Board meeting
Inter alia, to approve and take on record the audited financial results of the company for the year ended on March 31, 2011 and to consider payment of interim dividend and recommendation of final dividend for the Financial year 2010-2011.
Jan 2011
4 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2010.
Oct 2010
5 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on September 30, 2010.
Jul 2010
7 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on June 30, 2010.
Apr 2010
5 Apr · Board meeting
Inter alia, to approve and take on record the audited financial results of the Company for the year ended on March 31, 2010 and to consider recommendation of payment of dividend, if any, for the year 2009-2010.
Jan 2010
1 Jan · Board meeting
Inter-alia, to approve and take on record the unaudited financial results of the Company for the quarter ended on December 31, 2009.
Oct 2009
1 Oct · Board meeting
Meeting on 22 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
6 Jul · Board meeting
Meeting on 23 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Apr 2009
1 Apr · Board meeting
To approve and take on record the audited financial results of the company for the year ended on March 31, 2009 and to consider recommendation of payment of dividend, if any, for the year 2008-2009
Jan 2009
9 Jan · Board meeting
Meeting on 21 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Jul 2008
1 Jul · Board meeting
Meeting on 17 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
4 Apr · Board meeting
Inter-alia,to approve and take on record the audited financial results of the Company for the year ended on March 31, 2008 and to consider recommendation of payment of dividend, if any, for the year 2007-2008.
Jan 2008
7 Jan · Board meeting
Inter alia, to approve/ take on record the audited financial results of the Company for the quarter ending December 31, 2007.
Oct 2007
8 Oct · Board meeting
Inter alia, to approve/ take on record the audited financial results of the Company for the quarter and half year ending September 30, 2007.
Jun 2007
25 Jun · Board meeting
Inter alia, to approve / take on record the audited financial results of the Company for the quarter ended on June 30, 2007.
Apr 2007
4 Apr · Board meeting
Inter-alia to approve / take on record the audited financial results of the Company for the year ended on 31st March, 2007 and to consider recommendation of payment of dividend, if any, for the year 2006-2007.
Jan 2007
2 Jan · Board meeting
Inter alia, to approve / take on record the audited financial results of the Company for the quarter ending on 31st December, 2006.